ABSTRACT
The objective of this study was to determine the clinical characteristics of multiple sclerosis (MS) in African American (AA) patients in the New York State Multiple Sclerosis Consortium (NYSMSC) patient registry. The NYSMSC is a group of 18 MS centers throughout New York State organized to prospectively assess clinical characteristics of MS patients. AAs comprise 6% (329) of the total NYSMSC registrants (5602). Demographics, disease course, therapy, and socioeconomic status were compared in AA registrants versus nonAfrican Americans (NAA). There was an increased female preponderance and a significantly younger age at diagnosis in the AA group. AA patients were more likely to have greater disability with increased disease duration. No differences were seen in types of MS and use of disease modifying therapies. Our findings suggest a racial influence in MS. Further genetic studies that consider race differences are warranted to elucidate mechanisms of disease susceptibility.
Subject(s)
Black or African American , Multiple Sclerosis/ethnology , Multiple Sclerosis/physiopathology , Adult , Autoimmune Diseases/complications , Cognition Disorders/ethnology , Cognition Disorders/etiology , Cognition Disorders/psychology , Disabled Persons , Employment , Female , Humans , Logistic Models , Male , Medicaid , Multiple Sclerosis/complications , Multiple Sclerosis/genetics , Multiple Sclerosis/psychology , New York/ethnology , Prospective Studies , Registries , White PeopleABSTRACT
Intravenous gamma globulin (IVIg) is used in the treatment of immunologic diseases that affect the entire neuroaxis, including the brain, spinal cord, peripheral nerves, muscles, and neuromuscular junction. The panel reviewed the available literature on the use of IVIg in order to evaluate the efficacy of this therapy in neuroimmunologic diseases. In prospective, rigorously controlled, double-blinded clinical trials, IVIg was found to have proven efficacy in the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, dermatomyositis, and Lambert-Eaton myasthenic syndrome. It was found to be probably effective in myasthenia gravis and polymyositis, and possibly effective in several other neuroimmunologic diseases. Further studies are needed to evaluate the use of IVIg for neuroimmunologic diseases in which its efficacy is suspected but not proven and to elucidate its mechanisms of action.
Subject(s)
Immune System Diseases/therapy , Immunoglobulins, Intravenous/therapeutic use , Nervous System Diseases/therapy , Clinical Trials as Topic , HumansABSTRACT
The authors used data collected prospectively during a multicenter trial in 133 patients with secondary progressive MS to assess the relative sensitivity of quantitative functional tests and traditional measures, including the Expanded Disability Status Scale (EDSS) and Ambulation Index. Quantitative functional measures worsened in 69% of patients during an average of 6 months of observation, whereas the Clinical Global Impression of Change worsened in 33% and the EDSS worsened in 25% of patients. These changes should be interpreted in the context of the test-retest reliability for each measure.
Subject(s)
Multiple Sclerosis/physiopathology , Humans , Prognosis , Prospective Studies , Sensitivity and SpecificityABSTRACT
Neurologic complications and cerebrospinal fluid (CSF) abnormalities are common in AIDS. We found that a substantial number of AIDS patients with neurologic involvement had oligoclonal IgG bands in CSF and sera by IEF. Using an IEF-Ag overlay technique, anti-gp120 antibody activity was demonstrated more frequently than anti-p24 antibody activity. These antibody activities exhibited restricted heterogeneity of their IEF pattern; this restriction may contribute to the relatively low titers of neutralizing antibody found in AIDS sera. None of the CSF and serum oligoclonal bands showed anti-HIV antibody activity, suggesting that they are directed against opportunistic agents or result from immunodysregulation.
Subject(s)
Acquired Immunodeficiency Syndrome/immunology , Antibodies, Viral/isolation & purification , Antibody Specificity , HIV/immunology , Retroviridae Proteins/immunology , Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/cerebrospinal fluid , Antibodies, Viral/physiology , Antigen-Antibody Reactions , Dementia/blood , Dementia/cerebrospinal fluid , Dementia/immunology , HIV Antibodies , HIV Core Protein p24 , HIV Envelope Protein gp120 , Humans , Immunoglobulin G/cerebrospinal fluid , Serum Albumin/cerebrospinal fluidSubject(s)
Motor Neurons/drug effects , Nerve Regeneration/drug effects , Salivary Glands/analysis , Salivary Proteins and Peptides/isolation & purification , Amyotrophic Lateral Sclerosis/immunology , Animals , Autoantibodies/immunology , Axons/drug effects , Axons/ultrastructure , Cell Survival/drug effects , Chick Embryo , Humans , Male , Mice , Mice, Inbred AKR/metabolism , Mice, Inbred BALB C/metabolism , Motor Neurons/ultrastructure , Salivary Proteins and Peptides/immunology , Salivary Proteins and Peptides/pharmacologyABSTRACT
Neuroleukin is a lymphokine product of lectin-stimulated T cells that induces immunoglobulin secretion by cultured human peripheral blood mononuclear cells. Neuroleukin acts early in the in vitro response that leads to formation of antibody-secreting cells, but continued production of immunoglobulin by differentiated antibody-secreting cells is neuroleukin-independent. Although the factor is not directly mitogenic, cellular proliferation is a late component of the response to neuroleukin. Neuroleukin does not have B-cell growth factor (BCGF) or B-cell differentiation factor (BCDF) activity in defined assays. Neuroleukin-evoked induction of immunoglobulin secretion is both monocyte- and T-cell-dependent.
Subject(s)
Growth Substances/physiology , Lymphokines/physiology , T-Lymphocytes/physiology , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/physiology , Bone Marrow/metabolism , Cell Line , Cells, Cultured , Deltaretrovirus/genetics , Glucose-6-Phosphate Isomerase , Growth Substances/genetics , Growth Substances/pharmacology , Humans , Immunity, Cellular/drug effects , Immunoglobulins/biosynthesis , Lectins/pharmacology , Leukemia/metabolism , Lymphokines/genetics , Lymphokines/pharmacology , Lymphoma/metabolism , Mice , Pokeweed Mitogens/pharmacology , Sequence Homology, Nucleic Acid , T-Lymphocytes/drug effectsABSTRACT
After the partial denervation or paralysis of a muscle, the remaining motor axon terminals may sprout fine, neuritic processes (terminal sprouts) which escape the endplate region of the neuromuscular junction. We previously identified a muscle-derived, protein antigen of 56,000 daltons (56 kD) which plays a necessary role in terminal sprouting. A panel of monoclonal antibodies have been produced against the 56-kD antigen, some of which also partially suppress motor axon terminal sprouting. These monoclonal antibodies define at least two different epitopes upon the surface of the antigen, one of which is necessary for it to effect its biological role in vivo.
Subject(s)
Antibodies, Monoclonal/physiology , Antigens/immunology , Axons/physiology , Immune Tolerance , Motor Endplate/physiology , Muscles/immunology , Nerve Regeneration , Neuromuscular Junction/physiology , Animals , Antibodies, Monoclonal/analysis , Antibody Specificity , Antigens/isolation & purification , Cell Fusion , Chromatography, Ion Exchange , Female , Hybridomas/analysis , Immune Sera , Male , Mice , Mice, Inbred ICR , Molecular Weight , Motor Endplate/immunology , Motor Neurons/physiology , Muscles/innervation , Rats , Rats, Inbred Lew , Rats, Inbred StrainsABSTRACT
A patient with characteristic clinical, histopathological, ultrastructural and family history of epidermolysis bullosa simplex (EBS) developed large acquired nevocytic nevi at the sites of some healing blisters. An isomorphic reaction may have initiated the development of these nevi. Such large acquired nevi should be considered in the differential diagnosis of large and giant congenital nevi which have the potential to evolve into malignant melanoma.
Subject(s)
Nevus, Pigmented/pathology , Skin/pathology , Adult , Epidermolysis Bullosa/complications , Epidermolysis Bullosa/pathology , Humans , Male , Nevus, Pigmented/complicationsABSTRACT
This study aimed to define the complete concentration-effect relationship for anticurare effects of 3,4-diaminopyridine (3,4-DAP) in the isolated sympathetic ganglion of the bullfrog. Synaptic transmission was monitored by extracellular and intracellular recordings of the postganglionic response to preganglionic stimulation. A previous study showed that in the bullfrog sympathetic ganglion 3,4-DAP caused stimulus-bound repetitive postganglionic responses (SBR) to each single preganglionic stimulus. The concentration-effect relationship for 3,4-DAP-induced SBR was bell-shaped, and the descending limb of the curve reflected progressive suppression of SBR while normal synaptic transmission was maintained. In the present study a detailed concentration-effect analysis of 3,4-DAP's anticurare action also resulted in a bell-shaped curve nearly congruent with that for SBR. SBR and anticurare effects of 3,4-DAP therefore occupy a common concentration-effect domain, and this suggests that a common mechanism (increased transmitter release) may account for both effects.
